Pharmacological and non-pharmacological treatment of obstructive hypertrophic cardiomyopathy

References

• Veselka J, Anavekar N, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet. 2017;389:1253–1267.
   PubMed Web of Science ®Google Scholar
• Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation. 1995;92:785–789.
   PubMed Web of Science ®Google Scholar
• Bick AG, Flannick J, Ito K, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am J Hum Genet. 2012;91:513–519.
   PubMed Web of Science ®Google Scholar
• Sen-Chowdhry S, Jacoby D, Moon J, et al. Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol. 2016;13:651–675.
   PubMed Web of Science ®Google Scholar
• Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995;92:1680–1692.
   PubMed Web of Science ®Google Scholar
• Wigle ED, Wilansky S. Diastolic dysfunction in hypertrophic cardiomyopathy. Heart Failure. 1987;3:82–93.
   Google Scholar
• Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303.
   PubMed Web of Science ®Google Scholar
• Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–2779.
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Maron BJ, Bonow RO, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. Circulation. 2011;2011(124):e783–e831.
   Google Scholar
• Sherrid MV. Drug therapy for hypertrophic cardiomyopathy: physiology and practice. Curr Cardiol Rev. 2016 Feb;12:52–65.
   PubMed Web of Science ®Google Scholar
• Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation. 1998;97:41–47.
   PubMed Web of Science ®Google Scholar
• Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35:847–851.
   PubMed Web of Science ®Google Scholar
• Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ Heart Fail. 2013;6:694–702.
   PubMed Web of Science ®Google Scholar
• Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:437–441.
   PubMed Web of Science ®Google Scholar
• Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med. 1982;307:997–999.
   PubMed Web of Science ®Google Scholar
• Pollick C, Kimball B, Henderson M, et al. Disopyramide in hypertrophic cardiomyopathy, I: hemodynamic assessment after intravenous administration. Am J Cardiol. 1988;62:1248–1251.
   PubMed Web of Science ®Google Scholar
• Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1988;62:1085–1088.
   PubMed Web of Science ®Google Scholar
• Kimball BP, Bui S, Wigle ED. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. Am Heart J. 1993;125:1691–1697.
   PubMed Web of Science ®Google Scholar
• Sigward U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211–214.
   PubMedGoogle Scholar
• Goodwin JF, Hollman A, Cleland WP, et al. Obstructive cardiomyopathy simulating aortic stenosis. Br Heart J. 1960;22:403–414.
   PubMedGoogle Scholar
• Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119:1085–1092.
   PubMed Web of Science ®Google Scholar
• Iacovoni A, Spirito P, Simon C, et al. A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J. 2012;33:2080–2087.
   PubMed Web of Science ®Google Scholar
• Olivotto I, Ommen SR, Maron MS, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: will there ever be a randomized trial? J Am Coll Cardiol. 2007;50:831–834.
   PubMed Web of Science ®Google Scholar
• Noseworthy PA, Rosenberg MA, Fifer MA, et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2009;104:128–132.
   PubMed Web of Science ®Google Scholar
• Liebregts M, Vriesendorp PA, Ten Berg JM. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of endorsement. J Am Coll Cardiol. 2017 Jul;25(70):481–488.
   Google Scholar
• Vriesendorp PA, Liebregts M, Steggerda RC, et al. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol HF. 2014;2:630–636.
   Google Scholar
• Steggerda RC, Damman K, Balt JC, et al. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. J Am Coll Cardiol Intv. 2014;7:1227–1234.
   Google Scholar
• Sorajja P, Ommen SR, Holmes DR Jr., et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126:2374–2380.
   PubMed Web of Science ®Google Scholar
• Samardhi H, Walters DL, Raffel C, et al. The long-term outcomes of transcoronary ablation of septal hypertrophy compared to surgical myectomy in patients with symptomatic hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv. 2014;83:270–277.
   PubMed Web of Science ®Google Scholar
• Liebregts M, Vriesendorp PA, Mahmoodi BK, et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol HF. 2015;3:896–905.
   Google Scholar
• Ten Cate FJ, Soliman OI, Michels M, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010;3:362–369.
   PubMed Web of Science ®Google Scholar
• Qin JX, Shiota T, Lever HM, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol. 2004;93:171–175.
   PubMed Web of Science ®Google Scholar
• McCann GP, Van Dockum WG, Beek AM, et al. Extent of myocardial infarction and reverse remodeling assessed by cardiac magnetic resonance in patients with and without right bundle branch block following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2007;99:563–567.
   PubMed Web of Science ®Google Scholar
• Cho YH, Quintana E, Schaff HV, et al. Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy-mechanisms of obstruction and outcomes of reoperation. J Thorac Cardiovasc Surg. 2014;148:909–915.
   PubMed Web of Science ®Google Scholar
• Sorajja P. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of balance. J Am Coll Cardiol. 2017 Jul;25(70):489–494.
   Google Scholar
• Qintar M, Morad A, Alhawasli H, et al. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. Cochrane Database Syst Rev. 2012;5:CD008523.
   Google Scholar